Ospemifene, an oral SERM for dyspareunia of menopause: Is it being underutilized?

Article Type
Changed
Mon, 04/01/2019 - 11:30

Estrogen and androgen deficiency from menopause causes vulvovaginal and urogenital changes and a plethora of symptoms, most prominently dyspareunia. 

Read the supplement and earn CME credit for your knowledge of the following:

  • The pathophysiology of dyspareunia due to vulvovaginal atrophy (VVA) of menopause.
  • The underrecognition and undertreatment of dyspareunia due to VVA.
  • Efficacy results of randomized placebo controlled trials of ospemifene.
  • Adverse events associated with ospemifene.
  • Safety data of ospemifine as well as other oral selective estrogen receptor modulators and estrogens.

 

Click on the image above or here to read the supplement and earn credit

Sponsor
This activity is supported by an educational grant from Duchesnay
Publications
Topics
Sections
Sponsor
This activity is supported by an educational grant from Duchesnay
Sponsor
This activity is supported by an educational grant from Duchesnay

Estrogen and androgen deficiency from menopause causes vulvovaginal and urogenital changes and a plethora of symptoms, most prominently dyspareunia. 

Read the supplement and earn CME credit for your knowledge of the following:

  • The pathophysiology of dyspareunia due to vulvovaginal atrophy (VVA) of menopause.
  • The underrecognition and undertreatment of dyspareunia due to VVA.
  • Efficacy results of randomized placebo controlled trials of ospemifene.
  • Adverse events associated with ospemifene.
  • Safety data of ospemifine as well as other oral selective estrogen receptor modulators and estrogens.

 

Click on the image above or here to read the supplement and earn credit

Estrogen and androgen deficiency from menopause causes vulvovaginal and urogenital changes and a plethora of symptoms, most prominently dyspareunia. 

Read the supplement and earn CME credit for your knowledge of the following:

  • The pathophysiology of dyspareunia due to vulvovaginal atrophy (VVA) of menopause.
  • The underrecognition and undertreatment of dyspareunia due to VVA.
  • Efficacy results of randomized placebo controlled trials of ospemifene.
  • Adverse events associated with ospemifene.
  • Safety data of ospemifine as well as other oral selective estrogen receptor modulators and estrogens.

 

Click on the image above or here to read the supplement and earn credit

Publications
Publications
Topics
Article Type
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Gate On Date
Wed, 01/30/2019 - 13:45
Un-Gate On Date
Wed, 01/30/2019 - 13:45
Use ProPublica
CFC Schedule Remove Status
Wed, 01/30/2019 - 13:45
Hide sidebar & use full width
render the right sidebar.